Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. Macaluso FS, et al. Among authors: orlando e, orlando a, orlando r. Scand J Gastroenterol. 2017 Sep;52(9):981-987. doi: 10.1080/00365521.2017.1333626. Epub 2017 May 29. Scand J Gastroenterol. 2017. PMID: 28554266
Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.
Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Macaluso FS, et al. Among authors: orlando e, orlando a, orlando r. Dig Liver Dis. 2017 Feb;49(2):157-162. doi: 10.1016/j.dld.2016.10.001. Epub 2016 Oct 14. Dig Liver Dis. 2017. PMID: 27876682
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, Cappello M, Morreale GC, Siringo S, Privitera AC, Ferracane C, Belluardo N, Alberghina N, Ventimiglia M, Rizzuto G, Renna S, Cottone M, Orlando A. Macaluso FS, et al. Among authors: orlando a, orlando r. Dig Liver Dis. 2018 Jul;50(7):675-681. doi: 10.1016/j.dld.2018.02.013. Epub 2018 Mar 1. Dig Liver Dis. 2018. PMID: 29576495
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. Macaluso FS, et al. Among authors: orlando a, orlando r. Inflamm Bowel Dis. 2021 Jan 19;27(2):182-189. doi: 10.1093/ibd/izaa036. Inflamm Bowel Dis. 2021. PMID: 32083291
Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.
Renna S, Orlando E, Macaluso FS, Maida M, Affronti M, Giunta M, Sapienza C, Rizzuto G, Orlando R, Dimarco M, Cottone M, Orlando A. Renna S, et al. Among authors: orlando e, orlando a, orlando r. Aliment Pharmacol Ther. 2016 Aug;44(3):310-1. doi: 10.1111/apt.13692. Aliment Pharmacol Ther. 2016. PMID: 27375103 Free article. No abstract available.
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A. Renna S, et al. Among authors: orlando a, orlando r. Dig Liver Dis. 2018 Dec;50(12):1292-1298. doi: 10.1016/j.dld.2018.06.008. Epub 2018 Jun 22. Dig Liver Dis. 2018. PMID: 30007516
780 results